Results 121 to 130 of about 7,937 (220)

Amyloidosis in the cardiovascular system [PDF]

, 2016
In the most industrialized countries with a high degree of urbanization (including Ukraine), the leading cause of morbidity and mortality is occupied by diseases of the cardiovascular system.
Getmans’ka, V.
core  

Transthyretin Amyloid Cardiomyopathy: Diagnosis and Management

Current Cardiovascular Risk Reports
Abstract Purpose of Review This review examines the recent advances in transthyretin amyloid cardiomyopathy (ATTR-CM), focusing on evolving diagnostic strategies and emerging therapeutic interventions. We sought to analyze the current state of diagnostic modalities, evaluate newly approved disease-modifying therapies,
Anja Selland, Jalal Agakishi, Adam Devine, Valmiki R Maharaj   +3 more
openaire   +1 more source

Pittsburgh compound B positron emission tomography detects cardiomyopathy in hereditary transthyretin amyloidosis patients with negative bone scintigraphy: a pilot study

Frontiers in Nuclear Medicine
PurposeTo evaluate the effectiveness of positron emission tomography (PET) with [11C]-Pittsburgh Compound-B ([11C]PiB) for detecting transthyretin amyloid (ATTR) cardiomyopathy in patients with transthyretin gene (TTR) variants associated with reduced ...
Hendrea S. A. Tingen, Gilles N. Stormezand, Paul van Snick, Yingqi Hu, Paul Van Der Zwaag, Marish Oerlemans, Marish Oerlemans, Peter van der Meer, Bouke P. C. Hazenberg, Gert Luurtsema, Hans L. A. Nienhuis, Riemer H. J. A. Slart, Riemer H. J. A. Slart   +12 more
doaj   +1 more source

Prevalence of transthyretin amyloid cardiomyopathy in pacemaker patients

ESC Heart Failure
AbstractAimsTransthyretin amyloid cardiomyopathy (ATTR‐CM) is characterized by increased wall thickness, diastolic dysfunction and progressive heart failure symptoms. The disease may infiltrate the conduction system leading to conduction disturbances requiring an implantation of permanent cardiac pacemaker (PM), but the extent is unknown.
Aaseth, Eirik, Christiansen, Jon Runar
openaire   +4 more sources

Transthyretin Amyloid Cardiomyopathy

Journal of the American College of Cardiology, 2019
Frederick L. Ruberg, Martha Grogan, Mazen Hanna, Jeffery W. Kelly, Mathew S. Maurer   +4 more
openaire   +1 more source

Tafamidis therapy in transthyretin amyloid cardiomyopathy: a narrative review from clinical trials and real-world evidence

The Egyptian Heart Journal
Background Amyloidosis is a heterogeneous group of disorders caused by the extracellular deposition of insoluble misfolded proteins, leading to end-organ damage.
Ikponmwosa Jude Ogieuhi, Oshomoh Mark-Anthony Ugiomoh, Kudzaishe Muzofa, Kristen Callender, Johnson David Ayodeji, Nnokam Prayer Nnekachi, Barkavi Thiyagarajan, Emmanuel Obokhai Uduigwome, Abhay Kapoor, Moses Chukwuebuka Odoeke, Reem Gamaleldin Hassan Mohamed, Courage Idahor   +11 more
doaj   +1 more source

Extracellular Vesicles in Cardiac Amyloidosis: From Pathogenesis to Clinical Applications

Diagnostics
Cardiac amyloidosis is an infiltrative cardiomyopathy caused by extracellular deposition of misfolded proteins, most commonly immunoglobulin light chains (AL) or transthyretin (ATTR), with rarer forms occurring less frequently. AL amyloidosis arises from
Ashot Batikyan, Donclair Brown, Zainab Elahmadi, Joo Hee Park, Ashwin Ragupathi, Petras Lohana, Panagiotis Zoumpourlis, Priyansh Shah, Modak Vishakha, Martin Mcintosh, Michail Kladas, Priyanka Gokulnath, Michail Spanos   +12 more
doaj   +1 more source

In silico studies on potential binding sites of amyloid inhibitor compounds on amyloid beta peptide [PDF]

, 2012
The formation of structurally similar insoluble fibrillar protein aggregates, called amyloids, is known to cause several neuronal and non-neuronal degenerative diseases such as Alzheimer‟s disease, Parkinson‟s disease, Huntington‟s disease and Diabetes ...
Rudra, Sumon
core  

Transthyretin amyloid cardiomyopathy: The emerging role of cardiac amyloid imaging

Annals of the Academy of Medicine, Singapore, 2021
Sarah Ming Li, Tan, Yoke Ching, Lim, Ping, Chai, Lenith Tai Jit, Cheng, Ching Hui, Sia, Raymond Ching Chiew, Wong, Hoi Yin, Loi, Weiqin, Lin   +7 more
openaire   +2 more sources

A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathy [PDF]

, 2015

core   +1 more source